SynthesisThe Cochrane database of systematic reviews2004
Omega 3 fatty acids for prevention and treatment of cardiovascular disease.
Synthesis in The Cochrane database of systematic reviews, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06995586 (The Synergistic Action of Vitamins and Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery.), which is not on this map. Cited by 66 papers, 20 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Synergistic Action of Vitamins and Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery.
Who cites it
66 citing papers in PubMed, 20 syntheses or guidelines pooled it, 264 citations in OpenAlex.
- Interventions for primary prevention of cardiovascular disease: umbrella review of systematic reviews.Health technology assessment (Winchester, England) · 2025Pooled it
- Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.The Cochrane database of systematic reviews · 2020Pooled it
- Omega 3 fatty acid supplementation after myocardial infarction: a systematic review and meta-analysis.BMC cardiovascular disorders · 2019Pooled it
- Pooled it
- Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.The Cochrane database of systematic reviews · 2018Pooled it
- Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.Journal of atherosclerosis and thrombosis · 2018Guideline
- Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.The Cochrane database of systematic reviews · 2018Pooled it
- Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals.JAMA cardiology · 2018Pooled it
- Omega-3 fatty acids for the treatment of dementia.The Cochrane database of systematic reviews · 2016Pooled it
- Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration.The Cochrane database of systematic reviews · 2015Pooled it
- Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease.The Cochrane database of systematic reviews · 2014Pooled it
- Dietary advice for reducing cardiovascular risk.The Cochrane database of systematic reviews · 2013Pooled it
- Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials.BMC cardiovascular disorders · 2010Pooled it
- Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.The Journal of pediatrics · 2009Guideline
- Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review.Clinical cardiology · 2009Pooled it
- Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis.BMJ (Clinical research ed.) · 2009Pooled it
- Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2008Pooled it
- Primary prevention of CVD: diet and weight loss.BMJ clinical evidence · 2007Pooled it
- Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis.The Cochrane database of systematic reviews · 2007Pooled it
- Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review.BMJ (Clinical research ed.) · 2006Pooled it
6 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Updated by
Authors and funding
12 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt has been suggested that omega 3 (W3, n-3 or omega-3) fats from oily fish and plants are beneficial to health.
objectivesTo assess whether dietary or supplemental omega 3 fatty acids alter total mortality, cardiovascular events or cancers using both RCT and cohort studies. SEARCH STRATEGY: Five databases including CENTRAL, MEDLINE and EMBASE were searched to February 2002. No language restrictions were applied. Bibliographies were checked and authors contacted. SELECTION CRITERIA: RCTs were included where omega 3 intake or advice was randomly allocated and unconfounded, and study duration was at least six months. Cohorts were included where a cohort was followed up for at least six months and omega 3 intake estimated. DATA COLLECTION AND ANALYSIS: Studies were assessed for inclusion, data extracted and quality assessed independently in duplicate. Random effects meta-analysis was performed separately for RCT and cohort data. MAIN
resultsForty eight randomised controlled trials (36,913 participants) and 41 cohort analyses were included. Pooled trial results did not show a reduction in the risk of total mortality or combined cardiovascular events in those taking additional omega 3 fats (with significant statistical heterogeneity). Sensitivity analysis, retaining only studies at low risk of bias, reduced heterogeneity and again suggested no significant effect of omega 3 fats. Restricting analysis to trials increasing fish-based omega 3 fats, or those increasing short chain omega 3s, did not suggest significant effects on mortality or cardiovascular events in either group. Subgroup analysis by dietary advice or supplementation, baseline risk of CVD or omega 3 dose suggested no clear effects of these factors on primary outcomes. Neither RCTs nor cohorts suggested increased relative risk of cancers with higher omega 3 intake but estimates were imprecise so a clinically important effect could not be excluded. REVIEWERS'
conclusionsIt is not clear that dietary or supplemental omega 3 fats alter total mortality, combined cardiovascular events or cancers in people with, or at high risk of, cardiovascular disease or in the general population. There is no evidence we should advise people to stop taking rich sources of omega 3 fats, but further high quality trials are needed to confirm suggestions of a protective effect of omega 3 fats on cardiovascular health. There is no clear evidence that omega 3 fats differ in effectiveness according to fish or plant sources, dietary or supplemental sources, dose or presence of placebo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.